Myelopathy but normal MRI: Where next?

Practical Neurology

Volumn 8, Issue 2, 2008, Pages 90-102

  Wong, Sui H ^a   Boggild, Mike ^a   Enevoldson, T Peter ^a   Fletcher, Nicholas A ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; AGED; BRAIN; CASE REPORT; DIFFERENTIAL DIAGNOSIS; FEMALE; HUMAN; MALE; MIDDLE AGED; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; REVIEW; SPINAL CORD; SPINAL CORD DISEASE;

ADOLESCENT; AGED; BRAIN; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; SPINAL CORD; SPINAL CORD DISEASES;

EID: 41449086089     PISSN: 14747758     EISSN: None     Source Type: Journal    
DOI: 10.1136/jnnp.2008.144121     Document Type: Review

References (76)

1. Moore AP, Blumhardt LD. A prospective survey of the causes of non-traumatic spastic paraparesis and tetrapartsis in 585 patients. Spinal Cord 1997;35:361-7.
2. Paty DW, Blume WT, Brown WF, et al. Chronic progressive myelopathy: investigation with CSF electrophoresis, evoked potentials and CT scan. Ann Neurol 1979;6:419-24.
3. Miska RM, Pojunas KW, McQuillen MP. Cranial magnetic resonance imaging in the evaluation of myelopathy of undetermined etiology. Neurology 1987;37:840-3.
4. Rocca MA, Moastronardo G. Horsfield MA, et al. Comparison of three MR sequences for the detection of cervical cord lesions in patients with multiple sclerosis. Am J Neurorodiol 1999;20:1710-16.
5. Thompson AJ, Montalban X, Barkhof F, et al. Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 2000;47:831-5.
6. Wingerchuk DM, Lennon VA, Pittock SJ, et al. Revised diagnostic criteria for neuromyelitis optica. Neurology 2006; 66:1485-9.
7. Alexandtr EL, Mlinow K, Lejewski JE, et al. Primary Sjogren's syndrome with central nervous system disease mimicking multiple sclerosis. Ann Intern Med 1986;104:323-30.
8. Williams CS, Butler E, Roman GC. Treatment of myelopathy in Sjögren's syndrome with a combination of prednisone and cyclophosphomide. Arch Neurol 2001;58:815-19.
9. Delalande S, de Seze J, Fauchais A, et al. Neurologic manifestations in primary Sjogrer's syndrome: a study of 82 patients. Medicine (Baltimore) 2004;83:280-91.
10. Vincent TL, Richardson MP, Mackworth-Young CG, et al. Sjögren's syndrome-associated myelopathy: response to immunosuppressive treatment. Am J Med 2003;114:145-8.
11. Thomas E, Hay EM, Hajeer A, et al. Sjogren's syndrome: a community-based study of prevalence and impact. Br J Rheumotol 1998;37:1069-76.
12. de Seze J, Dubucquoi S. Fauchais AL, et al. Alpha-fodrin autoantibodies in the differential diagnosis of MS and Sjogren syndrome. Neurology 2003;61:268-9.
13. de Seze J, Delalande S, Fauchais AL, et al. Myelopathies secordary to Sjögren's syndrome: treatment with monthly intravenous Cyclophosphamide associated with corticosteroids. J Rheumatol 2006;33:709-11.
14. de Seze J, Dovs D, Castelnova G, et al. The prevalence of Sjogren syndrome in patients with primary progressive multiple sclerosis. Neurology 2001;57:1359-63.
15. Pericot I, Brieva L, Tintore M, et al. Myelopathy in seronegative Sjogrer's syndrome and/or primary progressive multiple sclerosis. Mult Scler 2003;9:256-9.
16. Vitali C, Bombardieri S, Janssen R, et al. Classification criteria for Sjogren's syndrome: a revised version of the European criteria proposed by the American-European Consensus Group. Ann Rheum Dis 2002;61:554-8.
17. Mok CC, Lau CS, Chan EYT, et al. Acute transverse myelopathy in systemic lupus erythematosus: clinical presentation, treatment and outcome. J Rheumatol 1998;25:467-73.
18. Kovacs B, Lafferty TL, Brent LH, et al. Transverse myelopathy in systemic lupus erythematousus: an analysis of 14 cases and review of the literature. Ann Rheum Dis 2000;59:120-4.
19. Tan EM, Cohen AS, Fries JF, et al. The 1982 revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1982;25:1271-7.
20. Bogousslavky J, Hungerbuhler JP. Regli F. et al. Subacute myelopathy as a presenting manifestation of sarcoidosis. Acta Neurochir (Wien) 1982;65:193-7.
21. Saleh S, Saw C, Marzouk K, et al. Sarcoidosis of the spiral cord: literature review and report of eight cases. J Natl Med Assoc 2006;98:965-76.
22. Delaney P. NEurologic manifestations of sarcoidosis: review of literature with a report of 23 cases. Ann Intern Med 1977; 87:336-45.
23. Joseph FG, Scolding NJ. SArcoidosis of the nervous system. Pract Neurol 2007;7:234-44.
24. Pringle CE, Hudson AJ, Munoz DG, et al. Primary lateral sclerosis: clinical features, neuropathology and diagnostic criteria. Brain 1992;115:495-520.
25. Le Forestier N, Maisonobe T, Piquard A, et al. Does primary lateral sclerosis exist? A study of 20 patients and a review of the literature. Brain 2001;124:1989-99.
26. Gordon PH, Cheng B, Katz IB, et al. The natural history of primary lateral sclerosis. Neurology 2006;66:647-53.
27. Harding AE. The hereditary otaxias and related disorders. Edinburgh: Churchill Livingstone, 1984.
28. Fink JK. Advances in the hereditary spastic paraplegias. Exp Neurology 2003;184:S106-S110.
29. Moser HW. Adrenoleukodystrophy: phenotype, genetics, pathogenesis and therapy. Brain 1997;120:1485-508.
30. Powers JM. DeCiero DP, Ito M, et al. Adrenomyeloreuropathy: a neuropathologic review featuring its noninflammatory myelopathy. J Neuropath Exp Neurology 2000;59:89-102.
31. van Geel BM, Bezman L, Loes DJ, et al. Evolution of phenotypes in adult male patients with X-linked adrenoleukodystrophy. Ann Neurol 2001;49:186-94.
32. Bezman L, Moser AB, Raymond GV, et al. Adrenoleukodystrophy: incidence, new mutation rate, and results of extended family screening. Ann Neurol 2001;49:512-17.
33. Shaw-Smith CJ, Lewis SJG. Reid E. X-linked adrenoleukodystrophy presenting as autosomal dominant pure hereditary spastic parapartsis. JNNP 2004;75:686-8.
34. Lynch DR, Farmer JM. Balcer LJ, et al. Friedreich Ataxia: effects of genetic understanding or clinical evaluation and therapy. Arch Neurol 2002;59:743-7.
35. Vaher U, Napa A, Numniste A, et al. Four siblings with Hallervordan-Spatz disease. Brain Dev 2001;23:236-9.
36. Sakai T, Kawakami H. Machado-Josepth disease: a proposal of spastic paraplegic subtype. Neurology 1996;46:846-7.
37. Clarencon F, Trouze E, Leroy-Willig A, et al. Spastic paraparesis as a manifestation of Leber's disease. J Neural 2006; 253:525-6.
38. Jan MMS. Misdiagnosis in children with doparesponsive dystoria. Pediatr Neurol 2004;31:298-303.
39. Nygaard TG, Marsden CD, Fahn S. Dopa-resporsive dystonia: long-term treatment response and prognosis. Neurology 1991;41:174-81.
40. Moulignier A, Moulonguet A, Pialoux G, et al. Reversibile ALS-like disorder in HIV infection. Neurology 2001;57:995-1001.
41. Di Rocco A, Simpson DM. AIDS-associated vacuolar myelopathy. AIDS Patient Care STDs 1998;12:457-61.
42. Santosh CG, Bell JE, Best JJ. Spiral tract pathology in AIDS: post-mortem MRI correlation with neuropathology. Neuroradiology 1995;37:134-8.
43. Gotuzzo E, Cabrera J. Deza L, et al. Clinical characteristics of patients in Peru with human T cell lymphotropic virus type-I associated tropical spastic paraparesis. Clin Infect Dis 2004; 39:939-44.
44. Orland JR, Engstrom J, Fridley J, et al. Prevalence and clinical features of HTLV neurology disease in the HTLV Outcome Study. Neurology 2003;61:1588-94.
45. Osame M, Janssen R, Kubota H, et al. Nationwide surveyr of HTLV-1 associated myelopathy in Japan: association with blood transfusion. Ann Neurol 1990;28:50-6.
46. Linderbaum J, Healton EB, Savage DG, et al. Neuropsychiatric disorders caused by cobalamin deficiency in the absence of anemia or macrocytoss. N Engl J Med 1988;318:1720-8.
47. Kumar N. Crum B, Peterson RC, et al. Arch Neurol 2004; 61:762-6.
48. Jaiser SR, Duddy M. Copper deficiency masquerading as subacute combined degeneration of the cord and myelodysplastic syndrome. ACNR 2007;7:20-21.
49. Kumar N, AhIskog JE, Klein CJ, et al. Imaging features of copper deficiency mytlopathy: a study of 25 cases. Neuroradiology 2006; 48:78-83.
50. Kumar N, Gross JB, AhIskog JE. Copper deficiency myelopathy produces a clinical picture like subacute combined degeneration. Neurology 2004;63:33-9.
51. Lewis M, Howdle PD. The neurology of liver failure. OJM 200; 96:623-33.
52. Gospe Jr SM, Caruso RD, Clegg MS, et al. Paraparesis. hypermanganesaemia, and polycythaemia: a novel presentation of cirrhosis. Arch Dis Child 2000;83:439-42.
53. Nolte CH, Endres AS. Meisel M. Sensory ataxia in myelopathy with chronic hepatitis C virus infection. Neurology 2002;59:958.
54. Troisi R, Debruyne J. de Hemptinne B. Improvement of hepatic myelopathy after liver transplantation. N Engl J Med 1999;340:151.
55. Counsell C. Warlow C. Failure of presumed hepatic myelopathy to improve after liver transplantation. J Neurol Neurosurg Psychiatry 1996; 60:590.
56. Yaldizli O. Johansson U, Gizewski ER, et al. Copper deficiency myelopathy induced by repetitive parerteral zinc supplementation during chronic haemodialysis. J Neurol 2006;253:1507-9.
57. Tampa K, Miyauchi Y, Irabu N, et al. HTLV-1 associated myelopathy in a patient with chronic renal failure. Nephron 1994; 66:351-3.
58. Novy J, Carruzzo A, Maeder P, et al. Spinal cord schaemia: clinical and imaging patterns, pathogenesis, and outcomes in 27 patients. Arch Neurol 2006;63:1113-20.
59. Loher TJ, Bassetti CL, Lovblad KO, et al. Diffusion-weighted MRI in acute spinal cord ischaemia. Neuroradiology 2003; 45:557-61.
60. Bammer R, Herneth AM, Maier SE, et al. Line scan diffusion imaging of the spine. Am J Neuroradiol 2003;24:5-12.
61. van Dijk JMC, TerBrugge KG. Willinsky RA, et al. Multidisciplinary management of spinal dural arteriovenous fistulas: clinical presentation and long term follow-up in 49 patients. Stroke 2002; 33:1578-83.
62. Jellema K, Canta LR, Tijssen CC, et al. Spinal dural arteriovenous fistula: clinical features in 80 patients. JNNP 2003; 74:1438-40.
63. Hurst RW, Kenyon LC, Lavi E, et al. Spinal dural arteriovenous fistula: the pathology of venous hypertensive myelopathy. Neurology 1995;45:1309-13.
64. Spetzler RF, Detwiler PW, Riina HA, et al. Modified classification of spinal cord vascular lesions. J Neurosurg (Spine 2) 2002; 96:145-56.
65. Saraf-Lavi E, Bowen BC, Quencer RM, et al. Detection of spinal dural arteriovenous fistulae with MR imaging and contrast-enhanced MR angiograpny: sensitivity. specificity and prediction of vertebral level. Am J Neuroradiol 2002;23:858-67.
66. Romper AH, Ayata C, Adelman L. Vasculitis of the spinal cord. Arch Neurol 2003;60:1791-4.
67. Marie RM. Le Biez E. Bussom P, et al. Nitrous oxide a nestesia-associated myelopathy. Arch Neurol 2000;57:380-2.
68. Sreeja VG, Nagahara N, Li Q, Minami M. New aspects in pathogenesis of konzo: neural cell damage directly caused by linamarin contained in cassava (Marihot esculenta Crantz). Br J Nutrition 2003; 90:467-72.
69. Rudnicki SA. Dalmau J. Paraneoplastic syndromes of the spinal cord, nerve and muscle. Muscle Nerve 2000;23:1800-18.
70. Graus F, Keime-Guibert F, Rene R, et al. Anti-Hu-associated paraneoplastic encephalomyelitis: analysis of 200 patients. Brain 2001;124:1138-48.
71. Hughes M, Ahern V, Kefford R, et al. Paraneoplastic myelopathy at diagnosis in a patient with pathologic stage 1A Hodgkin disease. Cancer 1992;70:1598-600.
72. Glantz MJ, Biran H, Myers ME, et al. The radiographic diagnosis and treatment of paraneoplastic central nervous system disease. Cancer 1994;73:168-75.
73. Younes-Mhenni S. Janier MF, Cinotti L, et al. FDG-PET improves tumour detection in patients with paraneoplastic neurological syndromes. Brain 2004;127:2331-8.
74. Glass J, Hochberg FH, Miller DC. Intravascular lymphomatosis: a systemic disease with neurologic manifestations. Cancer 1993; 71:3156-64.
75. Beristain X, Azzarelli B. The neurological masquerade of intravascular lymphomatosis. Arch Neurol 2002;59:439-43.
76. Baehring JM, Henchcliffe C, Ledezmo CJ, et al. Intravascular lymphoma: magnetic resonance imaging correlates of disease dynamics within the central nervous system. JNNP 2005;76:540-4.